Company to Unveil Innovative Upgrades for Quell Wearable Pain
Relief Technology
LAS VEGAS--(BUSINESS WIRE)--
NeuroMetrix,
Inc. (Nasdaq: NURO, NUROW) Building on sales to over 50,000 chronic
pain sufferers who have tried Quell® since its launch in June
2015, NeuroMetrix announced today that it will unveil innovative
upgrades to the company's 100% drug free wearable pain relief technology
at CES 2017 (booth #43421) in Las Vegas.
On Friday January 6, NeuroMetrix President & CEO, Shai N. Gozani, MD,
PhD will participate in a panel discussion at The Digital Health Summit
at CES. The panel, Digital
Health Delivers Personalized Power to the People, will take
place, from 2:45-3:15 p.m. (Venetian, Level 4, Lando 4303). The
panelists will discuss how digital health tools are giving consumers the
power to manage their health and wellness like never before.
About International CES
The International Consumer Electronics Show (International CES)
showcases more than 3,800 exhibiting companies, including manufacturers,
developers and suppliers of consumer technology hardware, content,
technology delivery systems and more; a conference program with more
than 300 conference sessions and more than 165K attendees from 150
countries.
For 50 years, CES has been the launch pad for new innovation and
technology that has changed the world. Held in Las Vegas every year, it
is the world's gathering place for all who thrive on the business of
consumer technologies and where next-generation innovations are
introduced to the marketplace.
About Quell
Quell is designed for millions of people suffering from chronic pain.
The advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared by
the FDA for treatment of chronic pain without a prescription. In a
recent study, 81% of Quell users reported an improvement in their
chronic pain. Quell users can start, stop, and adjust therapy discreetly
via the optional Quell Relief App. Quell also offers advanced sleep
tracking that provides feedback on eight dimensions of sleep including
sleep duration, quality, body position, time out of bed, and repetitive
leg movements throughout the night. Quell was the winner of the 2016
SXSW (South by Southwest) Innovation Award for Best Wearable Technology.
Quell is available at select healthcare professionals and retailers.
Visit QuellRelief.com
for more information.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company's lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161222005762/en/
NeuroMetrix, Inc.
Thomas T. Higgins,
781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
